Oxiracetam was originally introduced by an Italian pharmaceutical company, ICF, in 1988. The mechanisms of action for this nootropic is unknown, however it is believed that it may have stimulatory effects on acetylcholine receptors as well as glutamatergic NMDA receptors. Clinical studies have shown that administering oxiracetam allows for benefits in logical efficacy, concentration, memory, attentiveness and spatial adaptation.
$11.99 – $57.99
Oxiracetam Capsules | 800 mg |
Third Party COA
Oxiracetam capsules was originally introduced by an Italian pharmaceutical company, ICF, in 1988. The mechanisms of action for this nootropic is unknown, however it is believed that it may have stimulatory effects on acetylcholine receptors as well as glutamatergic NMDA receptors. Clinical studies have shown that administering oxiracetam allows for benefits in logical efficacy, concentration, memory, attentiveness and spatial adaptation.
Oxiracetam is a water-soluble ampakine of the nootropic racetam chemical class purported to be more potent than Piracetam and Aniracetam. Unlike many of the other chemicals in the Racetam family, oxiracetam is not widely used as a prescription drug. One study compared both Piracetam and oxiracetam showing that both improved learning facilities, and also had varying benefits in comparison to each other.
Oxiracetam in one study was shown to have positive benefits in regards to learning and memory in animals. The study was conducted using the pole climbing test with animals healthy, aging, and suffering from acute cerebral impairment.Experimental behavioral studies with oxiracetam on different types of chronic cerebral impairment (Clin Neuropharmacol. 1986;9 Suppl 3:S19-26).
In a two stage double blind study, each stage lasting 26 weeks, oxiracetam was shown to improve cognitive function and simple reaction time compared to the placebo. In the twelve months after the study those taking the placebo showed poorer results, and the patients themselves seemed to favor the Oxiracetam. Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy (Acta Neurol (Napoli). 1993 Feb;15(1):44-52).
The recommended dosage is usually 2400 mg per day, taken in three 800 mg doses, one in the morning again in the afternoon and a final administration in the evening. It is sold in both tablet and powder form, generally of 750 mg each.
Oxiracetam is a Racetam and an ampakine that is promoted as a natural method of improving cognitive functions through the stimulation of ACh receptors, AMPA receptors and NMDA receptors. There have been clinical studies to suggest oxiracetam can improve perception, memory, focus, concentration, and alertness. In some studies, oxiracetam has been shown to increase simple reaction times. The reviews suggested that some may experience better motor functionality.
There are still many variables though that have to be looked at with improving cognitive abilities. As a result, it is very hard to determine just how effective oxiracetam would be for a specific person. It all comes down to their own needs and current cognitive ability as well as lifestyle choices.
*NOTE: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
|Dimensions||2 × 2 × 4 in|
20 Capsule Sample Pack, 40 Capsule Sample Pack, 60 Capsules, 90 Capsules (1 Bottle), 120 Capsules, 150 Capsules, 180 Capsules (2 Bottles)